Preclinically, LILRB4 STAR-T cells effectively eliminated LILRB4+ AML cells 358, with dual-epitope targeting demonstrating enhanced anti-leukemia activity in vivo. This evidence concerns the gene LILRB4 and acute myeloid leukemia.